Back to Search Start Over

An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival

Authors :
Francesco Mannavola
Mario Mandala
Annalisa Todisco
Vanna Chiarion Sileni
Marco Palla
Alessandro Marco Minisini
Laura Pala
Francesca Morgese
Lorenza Di Guardo
Luigia Stefania Stucci
Michele Guida
Alice Indini
Pietro Quaglino
Virginia Ferraresi
Riccardo Marconcini
Maria Chiara Tronconi
Ernesto Rossi
Olga Nigro
Marcella Occelli
Alessio Cortellini
Silvia Quadrini
Giuseppe Palmieri
Jacopo Pigozzo
Paolo Antonio Ascierto
Maria Grazia Vitale
Sabino Strippoli
Pier Francesco Ferrucci
Rossana Berardi
Giovanni Randon
Pietro Cardone
Giovanni Schinzari
Franco Silvestris
Marco Tucci
Source :
Frontiers in Oncology, Vol 10 (2020)
Publication Year :
2020
Publisher :
Frontiers Media S.A., 2020.

Abstract

BackgroundWe performed a multicenter retrospective observational study to investigate the impact of clinical–pathological features and therapeutic strategies on both the complications and survival of patients with bone metastases (BMs) from malignant melanoma.Patients and MethodsA total of 305 patients with melanoma and radiological evidence of BMs were retrospectively enrolled from 19 Italian centers. All patients received conventional treatments in accordance with each own treating physician’s practice. Both univariate and multivariate models were used to explore the impact of melanoma features, including skeletal-related events (SREs), and different treatments on both overall survival (OS) and time-to-SREs. The chi-squared test evaluated the suitability of several parameters to predict the occurrence of SREs.ResultsEighty-three percent of patients had metachronous BMs. The prevalent (90%) bone metastatic site was the spine, while 45% had involvement of the appendicular skeleton. Forty-seven percent experienced at least one SRE, including palliative radiotherapy (RT) in 37% of cases. No melanoma-associated factor was predictive of the development of SREs, although patients receiving early treatment with bone-targeted agents showed 62% lower risk and delayed time of SRE occurrence. Median OS from the diagnosis of bone metastasis was 10.7 months. The multivariate analysis revealed as independent prognostic factors the number of BMs, number of metastatic organs, baseline lactate dehydrogenase levels, and treatment with targeted therapy or immunotherapy. Subgroup analyses showed the best OS (median = 16.5 months) in the subset of patients receiving both immunotherapy and palliative RT.ConclusionBased on our results, patients undergoing immunotherapy and palliative RT showed an OS benefit suggestive of a possible additive effect. The apparent protective role of bone targeting agent use on SREs observed in our analysis should deserve prospective evaluation.

Details

Language :
English
ISSN :
2234943X
Volume :
10
Database :
Directory of Open Access Journals
Journal :
Frontiers in Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.f7e6e5a9fa7d4cde857b7f04aa464c7d
Document Type :
article
Full Text :
https://doi.org/10.3389/fonc.2020.01652